Inspec

Inspec EBITDA Margin

The EBITDA Margin of Inspec (6656.T) as of Oct 21, 2026 is 6.40 %. In the previous year, EBITDA Margin was 5.27 % — a change of 21.39% (higher).

EBITDA Margin

6.40 %

YoY

21.39%

Last updated:

EBITDA Margin of Inspec is 2026 6.40 % . EBITDA Margin of Inspec was 2025 5.27 % . It decreases by 21.39% higher compared to the previous year.

The Inspec EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2019
11.12 JPY
Jan 1, 2020
8.75 JPY
Jan 1, 2021
-20.87 JPY
Jan 1, 2022
1.70 JPY
Jan 1, 2023
6.96 JPY
Jan 1, 2024
-13.22 JPY
Jan 1, 2025
5.27 JPY
Jan 1, 2026
6.40 JPY
The Inspec EBITDA Margin history
YEAREBITDA MarginYoY
6.40 %+21.39%
5.27 %-139.86%
-13.22 %-289.99%
6.96 %+309.38%
1.70 %-108.14%
-20.87 %-338.56%
8.75 %-21.31%
11.12 %-184.55%
-13.15 %-273.85%
7.57 %-727.61%
-1.21 %-118.13%
6.65 %+15.62%
5.75 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Inspec Stock analysis

What does Inspec do? inspec Inc. generates revenue through three primary segments. The Semiconductor Package Substrates and Precision Substrate Inspection Equipment segment sells appearance inspection equipment for semiconductor package substrates and precision printed circuit boards used in smartphones, tablets, PCs, and wearable terminals. The Precision Substrate Manufacturing Equipment segment provides photoplotters, inkjet printers, and direct imaging devices along with maintenance services for printed circuit boards. The Digital Pathology Related Equipment segment develops and sells medical image processing systems, specifically whole slide imaging (WSI) for digital pathology applications. Customers include manufacturers of advanced digital devices requiring semiconductor inspection, PCB producers needing photoplotters and imaging devices, and healthcare providers utilizing whole slide imaging systems for pathology diagnostics. The company's products target the semiconductor, electronics manufacturing, and medical imaging sectors with specific applications in device assembly, PCB production, and medical diagnostics. inspec Inc. focuses on equipment for semiconductor package substrates, precision substrates, and digital pathology, serving clients in the electronics and healthcare industries. The firm's inspection and imaging solutions are tailored to meet the quality control needs of high-tech manufacturing and medical diagnostics, with no mention of additional revenue streams beyond these three segments. Inspec is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Inspec stock

EBITDA Margin of Inspec is 6.40 % in 2026.

EBITDA Margin of Inspec changed from 5.27 % to 6.40 %, representing a 21.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Inspec since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Inspec with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Inspec

All Key Metrics — Inspec